ALY688
Source ALY688 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
ALY688 is a synthetic 10‑amino‑acid peptide that mimics adiponectin by activating its cellular receptors. In pre‑clinical studies it has been examined as a tool to improve insulin sensitivity, reduce inflammation and fibrosis, and protect cardiac and skeletal muscle in rodent models of metabolic stress, iron overload, and Duchenne muscular dystrophy. The compound is not approved for any clinical indication and its human safety and efficacy remain untested.
Mechanism of Action
ALY688 binds to adiponectin receptors (AdipoR1/AdipoR2), triggering downstream signaling cascades that include AMPK, ACC, and p38‑MAPK phosphorylation. In muscle cells this enhances Akt and IRS‑1 activation, improving insulin‑stimulated glucose uptake. Inflammatory and fibrotic pathways are dampened through AMPK‑PGC‑1α–driven suppression of NF‑κB and TGF‑β. In iron‑overload models the peptide also induces FAM134B‑dependent ER‑phagy, relieving ER stress and restoring insulin signaling.
What the Research Shows
Cell‑based work in rat L6 myotubes showed that ALY688 increases AMPK, ACC and p38‑MAPK phosphorylation, augments basal and insulin‑stimulated glucose uptake, and reverses high‑glucose‑induced insulin resistance. In high‑fat/high‑sucrose‑fed mice, sub‑cutaneous dosing improved glucose tolerance. In mdx mice, a model of Duchenne muscular dystrophy, two‑month sub‑cutaneous treatment enhanced endurance, reduced muscle inflammation, oxidative stress, necroptosis and fibrosis, and activated the AMPK‑PGC‑1α axis. A blood‑based gene signature and phospho‑flow assay identified pharmacodynamic biomarkers after ALY688 administration in LPS‑challenged mice, showing lowered pro‑inflammatory cytokines and increased AMPK/p38‑MAPK activity. Iron‑overload mice treated with ALY688 displayed improved insulin sensitivity, reduced ER stress markers, and restored autophagic flux via ER‑phagy. Short‑term daily dosing prevented right‑ventricular cardiac fibrosis in young D2.mdx mice, correlating with reduced inflammatory macrophages and mitochondrial stress. All evidence is pre‑clinical; no human trials have been reported.
Reported Benefits
Across multiple rodent models, ALY688 has consistently improved insulin signaling and glucose handling, lowered inflammatory cytokine levels, and limited fibrotic remodeling in skeletal and cardiac muscle. It also mitigated iron‑induced ER stress through activation of selective ER‑phagy. These findings suggest potential therapeutic value for metabolic syndrome, iron‑related insulin resistance, and dystrophic muscle disease, although benefits have only been demonstrated in cells and animals.
Limitations of the Evidence
Evidence is confined to in‑vitro assays and mouse studies; no clinical data exist to confirm efficacy or optimal dosing in humans. The reported effects are short‑term and may not translate to chronic disease states. Potential conflicts of interest were disclosed in several studies, and the peptide’s pharmacokinetics, long‑term safety, and off‑target actions remain unknown.
Safety Considerations
The published abstracts do not describe adverse events or toxicity in the animal experiments, and no human safety data are available. Consequently, the safety profile of ALY688 is undefined, and any extrapolation to clinical use would be speculative. Careful toxicology and dose‑finding studies would be required before human exposure.
How It Is Administered
In the pre‑clinical work ALY688 was delivered by sub‑cutaneous injection in mice and applied directly to cultured cells. Formulation details are not provided, and no alternative routes have been evaluated. Human administration routes and dosage forms have not been established.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleLowSung HK, et al.2022-01-01T00:00:00.000000Z
- Journal ArticleLowDubuisson N, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleLowTang J, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleLowLone AH, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleLowNguyen K, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleLowGandhi S, et al.2025-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of molecule is ALY688?
ALY688 is a short synthetic peptide designed to mimic adiponectin and activate its receptors, thereby reproducing many of adiponectin’s metabolic and anti‑inflammatory actions.
Has ALY688 been tested in people?
No. All published data involve cell cultures and mouse models; there are no clinical trials or regulatory approvals for human use at this time.
Which conditions might ALY688 help with, based on the studies?
Pre‑clinical results suggest potential benefits for insulin resistance, metabolic syndrome, iron‑induced ER stress, muscle inflammation and fibrosis in Duchenne muscular dystrophy, and early cardiac fibrosis, but these effects have not been demonstrated in humans.
Are there any known side effects?
The abstracts do not report adverse effects in animal studies, but the lack of human data means safety and possible side effects are currently unknown.
How is ALY688 administered in research?
In mouse experiments the peptide is given by sub‑cutaneous injection; in laboratory studies it is added directly to cell culture media. No other routes have been described.
What is ALY688?
ALY688 is a synthetic 10‑amino‑acid peptide that mimics adiponectin by activating its cellular receptors. In pre‑clinical studies it has been examined as a tool to improve insulin sensitivity, reduce inflammation and fibrosis, and protect cardiac and skeletal muscle in rodent models of metabolic stress, iron overload, and Duchenne muscular dystrophy. The compound is not approved for any clinical indication and its human safety and efficacy remain untested.